Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.
Saved in:
| Title: | Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance. |
|---|---|
| Authors: | Chen Y; Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.; Department of Cellular and Genetic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, 200433, China., Liu QP; Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China., Yang SJ; School of Pharmacy, Jinan University, Guangzhou, 510632, China., Ding J; Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. jding@simm.ac.cn., Lu XY; School of Pharmacy, Jinan University, Guangzhou, 510632, China. luxy2016@jnu.edu.cn., Xie H; Cancer Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China. hxie@simm.ac.cn.; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, 528400, China. hxie@simm.ac.cn. |
| Source: | Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Jul 08. Date of Electronic Publication: 2026 Jul 08. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
